Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform ...

A new neoantigen T-cell player has launched with Neogene Therapeutics nabbing a major $110 million series A. The funding haul, a significant sum for a first round, was led by by EcoR1 Capital, Jeito ...

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies “Engineered T cell therapies have demonstrated ...

Raphaël Rousseau, M.D., Ph.D., is the latest biopharma vet to land at transatlantic biotech Neogene Therapeutics, where he joins a leadership bench of Kite and Bristol Myers Squibb veterans. Rousseau ...

AstraZeneca expanded its oncology portfolio Tuesday morning by announcing it reached an agreement to buy Neogene Therapeutics. The British pharma giant is purchasing the clinical-stage biotechnology ...

A new immunotherapy biotech company that launched three years ago in Europe with backing from local biotech magnate Arie Belldegrun has set up its U.S. headquarters in Belldegrun’s former haunt, the ...

Neogene Co-Founder and CEO Carsten Linnemann, PhD, AstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the ...

Neogene aims to begin Phase I clinical studies in 2022. Neogene Therapeutics Inc. has raised $110 million in financing to advance the development of neo-antigen T cell therapies to treat various types ...

T-cell therapy company Neogene Therapeutics is being purchased by multinational pharma giant AstraZeneca in a deal potentially worth as much as $320 million that could greatly strengthen the regional ...

NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...